Ozempic and Mounjaro’s smashing success is just the beginning for biopharma’s obesity-drug arms race

Ozempic and Mounjaro’s smashing success is just the beginning for biopharma’s obesity-drug arms race Eli Lilly and Novo Nordisk have revolutionized the weight loss and diabetes drug space. Now, a flood of other GLP-1 drugs are on the horizon. Read the article on Fast Company > Read More from the Global Wellness News ™

Stockholm-based MANTLE secures over €2.8 Million for Clean Skincare Expansion

Stockholm-based MANTLE secures over €2.8 Million for Clean Skincare Expansion Stockholm-based MANTLE, a company developing clean and clinical skincare since 2020, has secured over €2.8 million in a round led by London-based venture capital firm Venrex. The round brings the company’s total funding to date to more than €8 million. Read the article on EU Startups > Read More from the Global Wellness News ™

Save Your Cart
Share Your Cart